Best Investments for 2014
Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.
Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.
Adcetris delayed disease progression in Hodgkin lymphoma patients following a stem cell transplant.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.
Results from a phase III study of Alcobra's MDX in adult ADHD are expected within the next week.
Baxter has a hunger for cancer drugs with hair.
Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.
Gilead's goal is to create new versions of its blockbuster HIV combination therapies, replacing Viread with TAF.
The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.
Activist investor Alex Denner is gaining an ally on Ariad's Board.
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics
while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a
reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a
comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and
strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV